Target selection for antisense oligonucleotide induced exon skipping in the dystrophin gene
- 21 January 2003
- journal article
- Published by Wiley in The Journal of Gene Medicine
- Vol. 5 (6) , 518-527
- https://doi.org/10.1002/jgm.361
Abstract
Background: Duchenne muscular dystrophy (DMD) is an X‐linked recessive muscle wasting disorder characterised by the absence of the protein dystrophin. Antisense oligonucleotides have been used to re‐direct dystrophin pre‐mRNA processing by blocking sequences crucial to pre‐mRNA splicing, thereby inducing skipping of specific exons. We wished to determine which splicing motifs are most amenable as targets for antisense oligonucleotide induction of efficient and specific skipping of selected exons.Methods: Antisense oligonucleotides were directed at regions of dystrophin exon 19 involved in pre‐mRNA splicing, including the donor and acceptor splice sites and the exon splicing enhancer (ESE). Cultured myotubes were transfected with antisense oligonucleotides at various concentrations and studies undertaken to determine both specificity and efficiency of induced exon 19 skipping.Results: Antisense oligonucleotides as small as 12 nucleotides targeting the ESE induced consistent and specific skipping of only exon 19 in both human and normal and mdx mouse myotubes. Antisense oligonucleotides directed at the donor and acceptor splice sites also induced specific exon 19 skipping while mismatched antisense oligonucleotides could only induce skipping when delivered at higher concentrations. No other dystrophin exons were removed from the mature mRNA as a consequence of these antisense oligonucleotides treatments.Conclusions: Antisense oligonucleotides directed at the ESE tended to be marginally more efficient than those which targeted the donor or acceptor splice sites, based on their ability to induce specific skipping at lower concentrations. The specificity of exon removal does not appear to be a function of target selection, but may reflect the combination of the splicing motifs and position of that exon in the pre‐mRNA. Copyright © 2003 John Wiley & Sons, Ltd.Keywords
This publication has 42 references indexed in Scilit:
- In Vivoandin VitroCorrection of themdxDystrophin Gene Nonsense Mutation by Short-Fragment Homologous ReplacementHuman Gene Therapy, 2001
- Gene therapy and molecular approaches to the treatment of hereditary muscular disordersCurrent Opinion in Neurology, 2000
- Rescue of dystrophin expression in mdx mouse muscle by RNA/DNA oligonucleotidesProceedings of the National Academy of Sciences, 2000
- Hypothesis: naked plasmid DNA is taken up by cellsin vivo by a receptor-mediated processThe Journal of Gene Medicine, 2000
- The fate of individual myoblasts after transplantation into muscles of DMD patientsNature Medicine, 1997
- Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression.Proceedings of the National Academy of Sciences, 1995
- Becker muscular dystrophy with onset after 60 yearsNeurology, 1994
- Duchenne muscular dystrophy: Gene and gene product; mechanism of mutation in the geneJournal of Inherited Metabolic Disease, 1992
- Dystrophin: The protein product of the duchenne muscular dystrophy locusCell, 1987
- Complete cloning of the duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individualsCell, 1987